Nautilus Biotechnology, Inc. (NAUT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Nautilus Biotechnology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Nautilus Biotechnology, Inc. (NAUT) has returned 98.97% so far this year and 350.64% over the past 12 months.

Based on dividend-adjusted daily data since Jun 10, 2021, NAUT's average daily return is +0.04%, while the average monthly return is +0.19%. At this rate, your investment would double in approximately 30.4 years.

Historically, 47% of months were positive and 53% were negative. The best month was Nov 2025 with a return of +69.2%, while the worst month was Mar 2025 at -33.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.

On a daily basis, NAUT closed higher 46% of trading days. The best single day was Nov 3, 2025 with a return of +39.1%, while the worst single day was Mar 11, 2024 at -19.1%.

Nautilus Biotechnology, Inc. has an annualized alpha of -7.73%, beta of 1.63, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since June 11, 2021.

• This stock participated in 187.40% of S&P 500 Index downside but only 89.67% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NAUT ranks 96 for risk / return — in the top 96% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Nautilus Biotechnology, Inc. (NAUT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Nautilus Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Nautilus Biotechnology, Inc. was 94.19%, occurring on Sep 3, 2025. The portfolio has not yet recovered.

The current Nautilus Biotechnology, Inc. drawdown is 64.73%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Nautilus Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Nautilus Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.